retatrutide phase 2 trial results type diabetes 2 2024 ada demonstrate benefits of in obesity, diabetes, NASH Efficacy and Safety of Retatrutide – Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Three variants (p.Thr638Met, p.Gly708Ser, and p.Arg755Gly) were repeatedly and independently discovered in unrelated families

Really we need to address the big denominator of people out there getting nothing, no surgical or pharmaceutical help, who have given up trying, who've tried every diet and exercise in the book, and some of the older weight-loss medicines

PMID 40180935

The primary difference is tissue-binding affinity GHK-Cu shows higher affinity for type I collagen and heparan sulfate proteoglycans, while AHK-Cu binds more selectively to elastin

Frequently Asked Questions Q: Can this bundle replace GLP-1 medications? A: No

For the science, see What Is CagriSema